0714/25SCR019-18/R10RGB
Media Highlights
From the 2025 ASCO® Annual Meeting
3
Media Outlet Article / Coverage
Oncology Brothers
ASCO 2025 - Breast Cancer Highlights: INAVO120, SERENA-6,
VERITAC-2, DESTINY-Breast09, ASCENT-04
Oncology Education
ASCO® 2025 Highlights: Presenter Vignette – Erika Hamilton
Oncology Learning Network
Vepdegestrant Could Extend PFS for Certain Patients With ESR1-
Mutated Advanced Breast Cancer
Oncology News
ASCO 2025: Vepdegestrant Could Extend Progression-Free Survival
for Some People with ESR1-Mutated Advanced Breast Cancer
Oncology News Central
Vepdegestrant Improves PFS in ESR1-Mutated ER-Positive, HER2-
Negative Breast Cancer
PharmExec.com
Pfizer, Arvinas' Novel PROTAC ER Degrader Shows Significant
Survival Benefit in ER+/HER2- Advanced Breast Cancer
Pharmacy Times
ASCO 2025: Vepdegestrant's Efficacy and Safety in ER+/HER2-
Advanced Breast Cancer
Pharmacy Times
ASCO 2025: Vepdegestrant Shows Superiority to Fulvestrant in
ER+/HER2- Advanced Breast Cancer
The Pharma Letter
ASCO: Positive Phase III Results for Arvinas and Pfizer's
Vepdegestrant
Targeted Oncology
VERITAC-2: Vepdegestrant Boosts PFS in Pretreated ESR1-Mutant
Breast Cancer
Targeted Oncology
Vepdegestrant Shows PFS Advantage in ESR1-Mutant ER+/HER2−
Breast Cancer
Targeted Oncology
FDA Receives Vepdegestrant NDA for ESR1-Mutated Breast Cancer
Targeted Oncology
Dr Hamilton on Emi-Le: A Novel Payload ADC in Breast Cancer
Targeted Oncology
Dr Hamilton: ASCO 2025 Breast Cancer Breakthroughs
Touch Oncology
#ASCO25: SERENA-6, DESTINY-Breast09, ASCENT-04 – Top Breast
Cancer Breakthroughs You Need to Know!
Touch Oncology
#ASCO25 Late-Breaker: How Vepdegestrant Could Reshape ER+
Breast Cancer
VJ Oncology
VERITAC-2: Vepdegestrant versus Fulvestrant in ER+/HER2- Breast
Cancer
VJ Oncology
Evaluating the Role of Vepdegestrant in Metastatic Breast Cancer
VJ Oncology
Early Phase I Findings for B7-H4-Directed ADC Emi-Le in Solid
Tumors
VJ Oncology
VJOncoAlert Journal Club | Vepdegestrant, a PROTAC Estrogen
Receptor Degrader, in Advanced Breast Cancer
Erika Hamilton, MD
SCRI
Continued ➔
